title: Analysis of the cytokine network among tumor necrosis factor alpha, interleukin-1beta, interleukin-8, and interleukin-1 receptor antagonist in monosodium urate crystal-induced rabbit arthritis.
abstract: In the present study, we analyzed the cytokine network among TNFalpha, IL-1beta, IL-8, and IL-1 receptor antagonist (IL-1Ra) in a rabbit experimental model of acute gout. The production of TNFalpha in synovial fluids reached the peak at 2 hours after the intra-articular injection of monosodium urate (MSU) crystals. The production of IL-1beta and IL-8 reached the first peak at 2 hours and the second peak at 9 and 12 hours, respectively. The production of endogenous IL-1Ra reached the peak at 9 hours. The source of TNFalpha and the first phase of IL-8 was synovial cells, whereas infiltrating leukocytes were the source of the second phase of IL-8 and also of IL-1beta and IL-1Ra. The production of TNFalpha was not altered by either anti-lL-8 IgG or IL-1Ra. The first IL-1beta peak was reduced only with a combination of anti-TNFalpha mAb and anti-lL-8 IgG, whereas the second peak was significantly reduced by either inhibitor. The first IL-8 peak was not altered with anti-TNFalpha mAb or IL-1 Ra, whereas the second IL-8 peak was reduced with IL-1Ra. Anti-TNFalpha mAb or anti-lL-8 IgG significantly reduced the peak level of endogenous IL-1Ra. These cytokine inhibitors also attenuated the maximal leukocyte accumulation at 9 hours, but not the initial phase, which occurred within 2 hours. These results provide evidence that IL-8 and TNFalpha were responsible for the production of IL-1beta and IL-1Ra, and that IL-1beta was responsible for the second phase of IL-1beta and IL-8 production. Our data also suggest that the initial and the maximal phases of leukocyte influx are differently regulated. Finally, the intravenous injection of colchicine inhibited neutrophil infiltration without affecting the production of TNFalpha or the first peak of IL-8, suggesting that colchicine inhibits MSU crystal-induced arthritis by directly inhibiting the migration of neutrophils.
authors.affiliation: Department of Pathology, Kumamoto University School of Medicine, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Matsukawa
authors.forename: T
authors.initials: T
authors.lastname: Yoshimura
authors.forename: T
authors.initials: T
authors.lastname: Maeda
authors.forename: T
authors.initials: T
authors.lastname: Takahashi
authors.forename: S
authors.initials: S
authors.lastname: Ohkawara
authors.forename: M
authors.initials: M
authors.lastname: Yoshinaga
mesh_terms: D000818:Animals; D000911:Antibodies, Monoclonal / Q000276:immunology; D001168:Arthritis / Q000139:chemically induced / Q000378:metabolism*; D002465:Cell Movement / Q000502:physiology; D003078:Colchicine / Q000494:pharmacology; D003460:Crystallization; D016207:Cytokines / Q000276:immunology / Q000378:metabolism*; D005260:Female; D006074:Gout Suppressants / Q000494:pharmacology; D007074:Immunoglobulin G / Q000276:immunology; D007150:Immunohistochemistry; D007375:Interleukin-1 / Q000378:metabolism*; D016209:Interleukin-8 / Q000378:metabolism*; D007958:Leukocyte Count; D007962:Leukocytes / Q000187:drug effects / Q000502:physiology; D009504:Neutrophils / Q000473:pathology; D011817:Rabbits; D017472:Receptors, Interleukin-1 / Q000037:antagonists & inhibitors*; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha / Q000378:metabolism*; D014527:Uric Acid / Q000494:pharmacology
chemical_list: D000911:Antibodies, Monoclonal; D016207:Cytokines; D006074:Gout Suppressants; D007074:Immunoglobulin G; D007375:Interleukin-1; D016209:Interleukin-8; D017472:Receptors, Interleukin-1; D011994:Recombinant Proteins; D014409:Tumor Necrosis Factor-alpha; D014527:Uric Acid; D003078:Colchicine